Clearview

Clearview Lifestyle Image Strip

For the qualitative detection of IgG antibodies specific to helicobacter pylori



About H. pylori

 

Helicobacter pylori (H. pylori) is a gram negative, multiflagellate, microaerophilic, spiral shaped bacterium. It is found in the stomach, deep in gastric pits, adhering to the surface of epithelial cells mainly beneath the protective gastric mucus layer. In this environment, H. Pylori is able to thrive free from the competition of other micro-organisms.

 

Before 1983, when this bacterium was first confirmed to be associated with peptic ulcers, it was thought that they were caused by stress, spicy food and general lifestyle. At this time, the majority of patients with peptic ulcers were treated with long-term maintenance doses of acid-reducing medication, such as H2 blockers. Since the discovery of the link between the organism and ulcers it has now been found that H Pylori causes more than 90% of duodenal ulcers and 80% of gastric ulcers.

 

With this knowledge, appropriate antibiotic regimens can successfully eradicate H. pylori in most patients, with complete resolution of the mucosal inflammation and a minimal chance of ulcer recurrence.

 

H. pylori Infection

 

Over 50% of the world’s population is infected with H. pylori, but in some less developed countries it maybe as high as 80-90%. In the Western world (e.g. USA), H pylori is more prevalent among older adults (50+ years), with a predomination in groups such as black and Hispanic Americans and those in the lower socioeconomic groups. In other regions the age related prevalence differs and is extremely common in childhood in certain countries (e.g. China).

 

Illnesses H. pylori cause

 

Most people infected with H. pylori never suffer any symptoms related to the infection, but once someone is infected the organism (if left untreated), can live indefinitely in the stomach and may not cause any clinical illness until many years later. H pylori can cause chronic active, chronic persistent and atrophic gastritis in adults and children plus it causes duodenal and gastric ulcers. It does this as H. pylori weakens the protective mucus coating of the stomach and duodenum allowing gastric acid to get through to the sensitive lining beneath.

Infected persons with H. pylori have a 2 to 6 fold increased risk of developing gastric cancer and mucosal-associated-lymphoid-type (MALT) lymphoma as compared to uninfected persons.

 

Symptoms of an ulcer

 

Abdominal discomfort is the most common ulcer symptom and is usually characterised by a gnawing or burning pain in the epigastrum. This pain typically occurs when the stomach is empty, occurring 2-3 hours after a meal or in the early morning hours. It may last for a matter of minutes or for hours and may be relieved by food or antacid medications. Other less common symptoms include nausea, poor appetite, vomiting, bloating and burping.

It is important to contact a doctor immediately if any of the following systems are experienced: - sharp, sudden persistent stomach pain, black/bloody stools or bloody vomit as these could be signs of a more serious problem such as ulcer perforation, bleeding or obstruction.

 

H. pylori infection diagnosis

 

There is a number of methods that can be used to diagnose H pylori infection but they basically fall into two main categories- Invasive and Non-Invasive.

 

Invasive Tests

 

Invasive tests require a gastric biopsy sample and there are three major methods of detecting H. pylori in this category.

 

Culture - requires an experienced laboratory but allows precise identification and is necessary when antimicrobial susceptibility testing is desired. Nb. Cultures are typically incubated in microaerobic conditions for up to 10 days.

 

Histology - histological identification of organism is considered by many to be the gold standard of diagnostic tests but results are dependent upon the skill and experience of the observer and results maybe difficult to interpret if only a few organisms are present.

 

Rapid Urease test (CLO Test) - a biopsy sample is incubated on an agar based medium containing urea. If H. pylori is present in the sample, the bacterial urease converts urea to ammonia and a colour change indicator detects the subsequent pH rise in the medium. The test takes a minimum of one hour but its sensitivity is increased by longer incubation periods.

 

Non-Invasive Tests

 

Typically there are two types of non-invasive diagnostic tests for H. plyori: -

 

Serological tests (e.g. Clearview H. pylori test) that detect specific antibodies in response to the H pylori infection with blood or serum being the most common samples used. The sensitivity and specificity of these assays ranges between 80-95% dependent on the assay.

 

Urea Breath Test- In this test the patient is given either a C13 or C14 labelled urea to drink. If H. pylori is present it metabolises the urea rapidly and labelled carbon dioxide is expired in the patients breath. The labelled carbon dioxide is measured by mass spectrometry or scintillation counting respectively.

Eradication of H. pylori in patients with peptic ulcers

 

H. pylori should be eradicated in all H. pylori related ulcers whether it is active or not for the following reasons: -

 

  • It prevents relapses- Treatment has been found to reduce the relapse rate from 80% to less than 5%.
  • It prevents ulcers re-bleeding.
  • It’s more cost effective than anti-secretory therapy as it fewer endoscopies are needed, there are fewer clinic visits, there are lower drug costs and it results in less work days lost.

 

Treatment regimens for the eradication of H. pylori

 

H. pylori related peptic ulcer treatment usually consists of a combination drug therapy that kill the bacteria, reduces stomach acid and protects the stomach lining. Drugs used in the combination therapy are as follows: -

 

  • Antibiotics- Metronidazole, Tetracycline, Clarithromycin & Amoxicillin
  • Acid Suppressing drugs
  • H2 blockers-Cimetidine, Rantidine, Famotidine & Nizatidine
  • Proton Pump Inhibitors (PPI)-Omeprazole, Lansprazole & Rabeprazole
  • Stomach lining shield - Bismuth subsalicylate.

 

It is not recommended to treat H. pylori with a single medication so combination therapy should always be used. There are a number of combination therapies in common use e.g. dual, triple and quadruple, but at this time the most proven effective treatment is a 2-week course of triple therapy. This involves taking two antibiotics to kill the bacteria and either an acid suppressor or stomach-lining shield. This therapy regimen reduces ulcer symptoms, kills the bacteria and prevents recurrence in more than 90% of patients

 

Long-term consequences of H. pylori infection

 

A number of studies have shown that there is a strong association between long-term H. pylori infection and the development of gastric cancer. Gastric cancer is the second most common cancer worldwide and it is most common in countries such as China and Colombia where there is an extremely high infection rate with H. Pylori.

 

Infection and prevention of H. pylori infection

 

It is not know exactly how H. pylori is transmitted or why some people become symptomatic while others do not. The most likely way of spreading the bacterium is from person to person via faecal-oral or oral-oral routes. It is also possible that the organism is spread through contaminated water. There are also documented cases of bacterial spread through the use of improperly cleaned and sterilised medical equipment such as endoscopes.

 

As the precise routes of transmission are unknown it is difficult to make any recommendations on how to reduce the spread of infection but in general as with many other infections, it is advisable to wash hands thoroughly, to eat food that has been properly prepared and drink water from a known clean source.

 

Some key economic facts about the peptic ulcers and H. pylori infection:

 

(From the USA as most studies on the economic impact have been conducted there)

 

  • Ulcers cause an estimated 1 million hospitalisation and 6500 deaths per annum.
  • The annual health care costs of peptic ulcer have been estimated to $6 billion
  • Studies indicate that curing an ulcer with antibiotics/triple therapy takes less time and cost one tenth of the amount of treating ulcer symptoms over a lifetime.
  • Acid-reducing maintenance therapy over 15-year period is estimated to cost $11,000. Compared to antibiotic therapy, which takes place over 14-21 days and costs less than a $1,000 over the same period.

 

Useful links:

 

Center for Disease Control and Prevention

National Institute of Diabetes & Digestive & Kidney Diseases

www.cdc.gov/ulcer

www.familydoctor.org/